oa Molecular Diagnosis and Vaccines - Serum vascular endothelial growth factor in childhood hematological malignancies
|Article Title||Serum vascular endothelial growth factor in childhood hematological malignancies|
|© Publisher:||Egyptian Association of Immunologists|
|Journal||Molecular Diagnosis and Vaccines|
|Affiliations||1 *Department of Pediatrics, Faculty of Medicine, Zagazig University, Egypt & **Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt|
|Publication Date||Jan 2004|
|Pages||37 - 44|
|Keyword(s)||angiogenesis inhibitors, children, enzyme linked immunosorbent assay, hematological malignancy, Hodgkin's lymphoma, leukemia, non-Hodgkins lymphoma and Vascular endothelial growth factor|
Vascular endothelial growth factor (VEGR) and its receptors are focus of interest because of their role in several biological processes that involve angiogenesis in non malignant and malignant states. This work aimed to valuate the serum level of vascular endothelial growth factor in children with different haematological malignancies and to correlate its level with the clinical manifestations and laboratory data of the disease. The study was carried out on 36 children with newly diagnosed hematological malignancies. They were divided into 3 groups. Group 1 included 20 patients with acute leukemia; 14 of them had acute lymphoblastic leukemia (ALL) and 6 had acute myeloblastic leukemia (AML). Group 2 included 10 patients with non-Hodgkins lymphoma (NHD), while group 3 included 6 patients with Hodgkin's lymphoma (HD). In addition, ten apparently healthy age and sex matched children as control group (group 4) were included. All groups were subjected to a complete history taking, full clinical examination and complete diagnostic work up to diagnose acute leukemia and lymphoma. Serum VEGF level was detected by enzyme linked immunosorbent assay (ELISA) at diagnosis. Investigations were repeated in the leukemic patients after induction of remission. The level of serum VEGF was significantly higher in all patients than control. However, no significant difference between the levels of serumVEGF in ALL and AML patients or in NHL and HD patients was detected. A significant (p<0.001) decrease in serum level VEGF was found in leukemic patients after induction of remission as compared with the newly diagnosed leukemic patients. SerumVEGF level showed significant correlation with the WBCs count in ALL and NHL groups, and with the platelet count in ALL, HD and NHL groups. SerumVEGF level correlated significantly with glandular enlargement in ALL, HD and in NHL groups, and with hepatomegaly in ALL and NHL groups. It can be concluded that serumVEGF may have a clinical relevance in the diagnosis and follow up of children with hematological malignancies and raises the possibility of using angiogenesis inhibitors as a novel therapeutic strategy in childhood hematological malignancies.
Article metrics loading...